Analysis of Postoperative Complications After 303 Sentinel Lymph Node Identification Procedures Using the SentiMag® Method in Breast Cancer Patients

Lorek, Andrzej; Stojčev, Zoran; Zarębski, Wojciech; Kowalczyk, Marek; Szyluk, Karol

doi:10.12659/msm.912758

Cited by 16 publications

(12 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A side effect of using MagTrace is a brown, bruise like discolouration of skin in a minority of patients which fades over time 15 . We did not experience this issue and chooses to inject the magnetic tracer deep to the dermis to avoid this.…”

Section: Discussionmentioning

confidence: 99%

Introducing SentiMag in a rural setting: a 5‐year experience

Sreedhar¹,

Maloney²,

Hudson³

2021

ANZ Journal of Surgery

View full text Add to dashboard Cite

Background The Sentimag device is a probe that contains a sensitive magnetometer which detects either an implantable magnetic marker (MagSeed) or an infectable superparamagnetic ironoxide nanoparticle tracer (MagTrace). MagSeed is used to localise impalpable breast lesions; MagTrace is used to identify sentinel lymph nodes. In Australasia, Sentinel lymph node (SLN) biopsy, using radioactive colloid injection, is a mainstay of prognostication in breast surgery in patients with a clinically negative axilla. In addition, radioactive seeds or hookwires have been used to detect impalpable breast lesions. Gisborne Hospital has been using the SentiMag device since June 2016 to both identify sentinel lymph nodes (Magtrace) and impalpable tumours (Magseed). This study gives perspective over more than 5 years on how this new technology can benefit patients and clinicians in the rural setting. Methods Patient data had been collected by the operative surgeon prospectively and corroborated with the coding department. Consecutive cases performed by a single surgeon were included in this study. Inclusion criteria were: (1) any patient who needed localisation of an impalpable breast lesion; (2) any patient who needed a sentinel lymph node biopsy; (3) cases were collected from January 2013 with the large majority of cases were collected between January 2015 and Jan 2020. Comparisons were made between patients with different localisation methods. Basic demographics were collected at the time of the surgery and outcomes then recorded. Staging, lymph node status, lymph node detection rates and complications were collected. Mode of tumour and sentinel node location was recorded. Financial data was collected from administrative staff via receipts and invoices of purchases to the hospital. Results Of the 125 patients included in this study: 23 underwent magnetic seed insertion; 15 underwent a hookwire insertion; 45 cases used MagTrace injection; 71 cases used radioactive colloid injection. There was a significantly higher detection rate of two or more sentinel nodes in the SentiMag group. (91% vs. 71.8%, p = 0.01). Neither complication rates, nor cancer detection rates were significantly different. Eighty‐four (67.2%) cases did not require tumour location. Conclusion SentiMag is safe to use in a rural setting. Using the SentiMag system can simplify care for patients and surgeons and was shown to be cost effective in our hospital.

show abstract

Section: Discussionmentioning

confidence: 99%

Introducing SentiMag in a rural setting: a 5‐year experience

Sreedhar¹,

Maloney²,

Hudson³

2021

ANZ Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…Sienna+ ® (~60 nm diameter) has exhibited adverse events which are not of serious severity and generally limited to discoloration or hyperpigmentation due to retention in tissues (Alvarado et al, 2019). Overall it has been deemed that the risk of complications is low (Lorek, Stojc ˇev, Zarębski, Kowalczyk, & Szyluk, 2019). Similarly, for ferumoxytol (Feraheme ® , ~30 nm diameter), adverse events due to infusion are rare (Akhuemonkhan, Parian, Carson, & Hutfless, 2018).…”

Section: Discussionmentioning

confidence: 99%

Mechanisms of nanoparticle radiosensitization

Kempson

2020

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Metal‐based nanoparticles applied to potentiating the effects of radiotherapy have drawn significant attention from the research community and are now available clinically. By improving our mechanistic understanding, nanoparticles are likely to evolve to provide very significant improvements in radiotherapy outcomes with only incremental increase in cost. This review critically assesses the inconsistent observations surrounding physical, physicochemical, chemical and biological mechanisms of radiosensitization. In doing so, a number of needs are identified for continuing research and are highlighted. The large degree of variability from one nanoparticle to another emphasizes that it is a mistake to generalize nanoparticle radiosensitizer mechanisms. Nanoparticle formulations should be considered in an analogous way as pharmacological agents and as a broad class of therapeutic agents, needing to be considered with a high degree of individuality with respect to their interactions and ultimate impact on radiobiological response. In the same way that no universal anti‐cancer drug exists, it is unlikely that a single nanoparticle formulation will lead to the best therapeutic outcomes for all cancers. The high degree of complexity and variability in mechanistic action provides notable opportunities for nanoparticle formulations to be optimized for specific indications. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Nanotechnology Approaches to Biology > Nanoscale Systems in Biology

show abstract

“…Our results concur that performing an SNB did not affect the oncological outcomes of almost all of our patients. The morbidity of SNB such as lymphoedema is approximately 7.5%, as well as giving rise to other known complications (shoulder stiffness, numbness, infection, etc) [ 8 , 12 ].…”

Section: Discussionmentioning

confidence: 99%

Sentinel Node Biopsy in Ductal Carcinoma in Situ: Is it Justifiable?

Al-Shurbasi¹,

Hirst²,

Kohlhardt³

2021

Cureus

View full text Add to dashboard Cite

Background: For invasive breast cancer, sentinel node biopsy (SNB) is an acceptable alternative to axillary node clearance (ANC), although in the recent era, its role is under review. In ductal carcinoma in situ (DCIS), the benefit of SNB is even less well defined. Despite this, guidelines still recommend that it is performed in selected cases of DCIS. The aim of our study was to evaluate the diagnostic value of performing SNB in DCIS. Methods: Patients with a diagnosis of DCIS who underwent axillary staging with SNB between 2008-2019 in our large volume tertiary centre were identified and included in the study. Results: Out of the 48 patients who were identified, four patients had a positive SNB (8%). Two of those patients were found to have micro metastatic disease. None of the patients with a positive SNB had local or systemic recurrence (median follow up: 40 months). One non-breast cancer-related mortality was reported. Two patients were identified who had recurrent disease, one with an invasive recurrence in the breast, and the other with systemic recurrence in the form of bone disease. Both of these patients had a negative SNB. Conclusion: Our results confirm that performing axillary staging with SNB in DCIS is not justifiable, as it does not affect patient outcomes. This supports the emerging evidence that being more surgically conservative may decrease morbidity without affecting patient survival.

show abstract

Analysis of Postoperative Complications After 303 Sentinel Lymph Node Identification Procedures Using the SentiMag® Method in Breast Cancer Patients

Cited by 16 publications

References 36 publications

Introducing SentiMag in a rural setting: a 5‐year experience

Introducing SentiMag in a rural setting: a 5‐year experience

Mechanisms of nanoparticle radiosensitization

Sentinel Node Biopsy in Ductal Carcinoma in Situ: Is it Justifiable?

Contact Info

Product

Resources

About